Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harvard Bioscience (HBIO) Payables (2016 - 2025)

Historic Payables for Harvard Bioscience (HBIO) over the last 17 years, with Q3 2025 value amounting to $5.2 million.

  • Harvard Bioscience's Payables fell 202.54% to $5.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.2 million, marking a year-over-year decrease of 202.54%. This contributed to the annual value of $4.8 million for FY2024, which is 1380.99% down from last year.
  • Per Harvard Bioscience's latest filing, its Payables stood at $5.2 million for Q3 2025, which was down 202.54% from $4.7 million recorded in Q2 2025.
  • Harvard Bioscience's Payables' 5-year high stood at $7.5 million during Q2 2021, with a 5-year trough of $4.7 million in Q2 2023.
  • Over the past 5 years, Harvard Bioscience's median Payables value was $5.7 million (recorded in 2024), while the average stood at $5.7 million.
  • In the last 5 years, Harvard Bioscience's Payables soared by 3127.67% in 2022 and then plummeted by 3074.89% in 2023.
  • Quarter analysis of 5 years shows Harvard Bioscience's Payables stood at $4.9 million in 2021, then skyrocketed by 31.28% to $6.4 million in 2022, then fell by 13.85% to $5.6 million in 2023, then fell by 13.81% to $4.8 million in 2024, then increased by 8.13% to $5.2 million in 2025.
  • Its last three reported values are $5.2 million in Q3 2025, $4.7 million for Q2 2025, and $4.8 million during Q1 2025.